Şunu aradınız:: antimuscarinic (İngilizce - Maltaca)

antimuscarinic activity
attività antimuskarinika

patients with prior oab antimuscarinic therapy
pazjenti li preċedentement ħadu terapija antimuskarinika għall-oab

antimuscarinic activity resides predominantly in the r-isomer.
attività anti- muskarinika tinsab l- iktar fl- isomeru r.

dose dependent antimuscarinic adverse reactions are likely to occur.
hemm possibilità qawwija ta’ reazzjonijiet avversi antimuskariniċi li jiddependu mid-doża.

patients with prior oab antimuscarinic therapy who discontinued due to insufficient effect
pazjenti li preċedentement ħadu terapija antimuskarinika għall-oab u waqqfuha minħabba effett insuffiċjenti

none of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine.
l-ebda wieħed minn dawn il-metaboliti m’għandu effett sinifikativ fuq l-attività anti-muskarinika ta’ fesoterodine.

glycopyrronium is a quaternary ammonium antimuscarinic with peripheral effects similar to those of atropine.
glikopirronju huwa antimuskariniku tal-ammonju kwaternarju b'effetti periferali simili għal dawk ta' atropine.

betmiga should also be administered with caution to patients taking antimuscarinic medications for the treatment of oab.
betmiga għandu jingħata wkoll b‟kawtela lil pazjenti li jkunu qed jieħdu mediċini antimuskariniċi għat-trattament ta‟ oab.

toviaz is a so called antimuscarinic medicinal product which reduces the activity of an overactive bladder and treats the symptoms.
toviaz huwa prodott mediċinali li jissejaħ antimuskariniku, li jnaqqas l- attivita eċċessiva tal - bużżieqa ta ’ l- awrina u jittratta s- sintomi.

as with other antimuscarinic agents, emselex may produce effects such as dizziness, blurred vision, insomnia and somnolence.
bħal mediċini oħra antimuskariniċi, emselex jista’ jikkawża effetti bħal sturdament, vista mċajpra, nuqqas ta’ rqad u tħeddil.

the chmp also noted that there were no major safety concerns with incruse, with side effects being manageable and similar to other antimuscarinic bronchodilator medicines.
is-chmp innota wkoll il ma kien hemm l-ebda tħassib maġġuri relatat mas-sigurtà b'incruse, bl-effetti sekondarji li huma maniġġevoli u simili għal mediċini bronkodilaturi antimuskariniċi oħrajn

due to the pharmacological properties of fesoterodine, treatment may cause mild to moderate antimuscarinic effects like dry mouth, dry eye, dyspepsia and constipation.
minħabba l-karatteristiċi farmakoloġiċi ta’ fesoterodine, it-trattament jista’ jirriżulta f’effetti anti- muskariniċi minn ħfief sa moderati bħal ma huma ħalq xott, għajnejn xotti, dispepsja u stitikezza.

the study population consisted of approximately 48% antimuscarinic treatment naïve patients as well as approximately 52% patients previously treated with antimuscarinic medication.
madwar 48% tal-popolazzjoni tal-istudju kienet tikkonsisti f‟pazjenti li ma ħadux kura antimuskarinika u madwar 52% tal-pazjenti li preċedentement kienu kkurati b‟mediċina antimuskarinika.

consistent with its antimuscarinic activity, umeclidinium/vilanterol should be used with caution in patients with urinary retention or with narrow-angle glaucoma.
b’mod konsistenti mal-attività antimuskarinika tiegħu, umeclidinium/vilanterol għandu jintuża b’kawtela f’pazjenti li jbatu minn żamma tal-awrina jew glawkoma tal-angolu dejjaq.

as with any other antimuscarinic agents, concomitant use of medicinal products that possess antimuscarinic properties, such as oxybutynin, tolterodine and flavoxate, may result in more pronounced therapeutic and side effects.
bħal ma jiġri bis-sustanzi antimuskariniċi l-oħrajn kollha, l-użu ta’ prodotti mediċinali oħra li għandhom effetti antimuskariniċi bħal oxybutynin, tolterodine u flavoxate, jista’ jwassal għal effetti terapewtiċi u sekondarji aktar qawwija.

as antimuscarinic bronchodilator medicines may have an effect on the heart and blood vessels, the company will continue to closely monitor the medicine’s cardiovascular effects and will carry out a further study in patients to identify any potential risks.
minħabba li l-mediċini bronkodilaturi antimuskariniċi jista' jkollhom effett fuq il-qalb u fuq il-vini, il- kumpanija sejra tkompli timmonitorja mill-qrib l-effetti kardjovaskulari tal-mediċina u sejra twettaq studju ulterjuri f'pazjenti sabiex tidentifika kwalunkwe riskji potenzjali.

as with other antimuscarinics, fesoterodine should be used with caution in patients with risk for qt- prolongation (e. g. hypokalaemia, bradycardia and concomitant administration of medicines known to prolong qt interval) and relevant pre-existing cardiac diseases (e. g. myocardial ischaemia, arrhythmia, congestive heart failure), (see section 4.8).
iskemja mijokardijaka, arritmija, insuffiċjenza tal- qalb konġestiva), (ara sezzjoni 4. 8).